Welcome to our dedicated page for Legend Biotech SEC filings (Ticker: LEGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Legend Biotech Corporation filings document foreign private issuer current reports, operating updates, governance actions, registration statements, and equity-plan disclosures for a cell therapy biopharmaceutical company. Its Form 6-K reports cover CARVYKTI® preliminary sales information received through the Janssen collaboration, quarterly and annual financial-result releases, corporate presentations, and clinical updates involving the CARTITUDE program and LUCAR-G39D.
The company’s regulatory disclosures also record board appointments and resignations, audit committee leadership, director compensation under restricted share unit plans, and related-party matters involving GenScript. Incorporated Form F-3 and Form S-8 references connect current reports with securities registration and incentive-plan filings, while risk language addresses forward-looking statements, product development, collaboration economics, and commercialization of CAR-T therapies.
Legend Biotech filed a Form 6-K highlighting early Phase 1 data for LB2501, an investigational in vivo CD19/CD20 dual‑targeting CAR-T therapy for relapsed/refractory B‑cell non-Hodgkin lymphoma. LB2501 is given as a single intravenous infusion without ex vivo cell manufacturing or lymphodepleting chemotherapy.
As of April 1, 2026, 12 patients were treated across two dose levels. At dose level 2, the objective response rate was 100% (6 of 6 patients), with a complete response rate of 83.3% (5 of 6), and all responses were ongoing at cutoff. Safety data showed no dose-limiting toxicities, serious adverse events, deaths, or immune effector cell-associated neurotoxicity; infusion reactions occurred in 75% of patients and cytokine release syndrome in 66.7%, all Grade 1–2. Pharmacokinetic data confirmed dose-dependent in vivo CAR-T expansion with cells detectable in blood for up to 116 days.
Legend Biotech reported new clinical data at ASCO 2026 for its investigational solid-tumor CAR-T LB2102 and for its approved multiple myeloma CAR-T, CARVYKTI®.
In an early Phase 1 study in relapsed or refractory small cell lung cancer or large-cell neuroendocrine carcinoma, LB2102 showed an objective response rate of 20% (4/20) and a disease control rate of 70% (14/20). At higher dose levels, responses improved to an objective response rate of 28.6% and disease control rate of 78.6%, with median disease control of 6.1 months and median duration of response of 6.5 months. Safety was described as manageable, with cytokine release syndrome in 30% of patients (all Grade ≤2) and ICANS in 15%.
For CARVYKTI®, new CARTITUDE-4 subgroup analyses showed progression-free and overall survival benefits across high-risk and standard-risk patients who responded to bridging therapy, with 30‑month overall survival rates above 85%. Additional pooled data described a low incidence of IEC-associated enterocolitis (1.2%) and detailed known serious risks such as CRS, neurologic toxicities, infections, prolonged cytopenias, secondary malignancies, and other adverse events, while CARVYKTI® remains approved and commercially available in 18 countries and has been used in more than 10,000 patients.
Legend Biotech is using the ASCO 2026 meeting to showcase both its approved multiple myeloma therapy CARVYKTI and its early solid-tumor CAR-T pipeline. The company will give a rapid oral presentation of preliminary Phase 1 data for LB2102, a DLL3‑targeted CAR‑T for relapsed or refractory small‑cell lung cancer and large‑cell neuroendocrine carcinoma, and present new CARVYKTI analyses from the CARTITUDE program, including cytogenetic subgroup results and immune effector cell‑associated enterocolitis data. CARVYKTI, a BCMA‑directed autologous CAR‑T, is approved for adults with relapsed or refractory multiple myeloma after at least one prior line of therapy and is commercially available in 18 countries, with more than 10,000 patients treated. Legend will also host an investor webcast on May 31, 2026, featuring clinicians discussing how CARVYKTI is changing the multiple myeloma treatment landscape. The filing includes extensive safety information on CARVYKTI, detailing rates and management of cytokine release syndrome, neurologic toxicities, infections, cytopenias, and secondary malignancies.
Legend Biotech reported strong top-line growth for the three months ended March 31, 2026, driven by rising CARVYKTI collaboration revenue, while losses narrowed meaningfully. Total revenue grew to $305.1 million from $195.0 million, mainly from collaboration revenue of $298.4 million tied to CARVYKTI sales with Janssen.
Net loss improved to $54.3 million from $101.0 million, and Adjusted Net Loss shrank to $10.5 million. Legend held $834.6 million in cash and time deposits and expects this to fund operations beyond 2026. CARVYKTI net trade sales reached approximately $597 million, with availability in 18 markets and over 300 sites, while R&D costs declined as major cilta‑cel trials completed dosing.
Legend Biotech Corporation reported preliminary net trade sales of approximately $597 million for CARVYKTI® for the quarter ended March 31, 2026. This figure comes from collaboration partner Janssen under an existing collaboration and license agreement and has not been independently verified by Legend Biotech.
Management has not yet finalized the financial statements for this period, so the ultimate revenue and gross profit that Legend Biotech will record may differ from this sales figure. The company notes that its independent registered public accountants have not audited or reviewed this data and emphasizes customary forward-looking statement and risk factor cautions.
Legend Biotech Corp Chief Executive Officer Ying Huang reported the sale of 9,936 ordinary shares on March 25, 2026. The weighted average price was $8.77 per ordinary share. According to the disclosure, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted share units. Following this transaction, Huang directly holds 247,438 ordinary shares.
LEGN filed a Form 144 reporting the proposed sale of 4,968 American Depositary Shares following restricted stock vesting on 03/20/2026. The filing lists trading on NASDAQ and records a prior sale by Ying Huang of 64,339 American Depositary Shares on 12/26/2025 for $1449074.23.
Legend Biotech Corp director Tomas J. Heyman has filed an initial ownership report outlining his equity position in the company. He directly holds 32,734 ordinary shares, which include 25,674 restricted share units that vest in staged quarterly installments beginning on March 20, 2026 and a larger tranche starting on June 20, 2026, subject to continued service. He also holds a share option over 30,000 ordinary shares at an exercise price of $23.27 per share, expiring on August 1, 2032. Of these option shares, 18,000 are immediately exercisable, with the remaining 12,000 vesting in two equal annual installments beginning on August 2, 2026. Each American Depositary Share represents two ordinary shares.
Legend Biotech Corp filed an initial insider ownership report for director Robin Meng on Form 3. This filing establishes Meng’s status as a reporting insider but shows no reported transactions or holdings, indicating that only insider status, not trading activity, is being disclosed at this time.